The proportion of people in the U.S. with pulmonary arterial hypertension related to the use of methamphetamine (Meth-PAH) increased by 93% between 2018 and 2022, a steeper increase than the one seen for the number of U.S. adults self-reporting methamphetamine use, a new study shows. The analysis found that Meth-PAH patients…
News
Winrevair (sotatercept-csrk), an injection therapy approved for adults with pulmonary arterial hypertension (PAH), is now covered by several of Canada’s publicly funded health programs. The therapy’s developer Merck, known as MSD outside the U.S. and Canada, announced that Winrevair has been added to the public drug formularies…
Measuring levels of tiny pieces of genetic material in the blood, known as microRNAs, may help identify group 2 pulmonary hypertension (PH), according to a new study. “We identified a set of circulating [microRNAs] that are differentially expressed in Group 2 PH and correlated with disease severity,” researchers wrote…
A study found that a naturally occurring signaling molecule called C-type natriuretic peptide (CNP) reduced the severity of pulmonary arterial hypertension (PAH) in mice. “This study highlights the important role of [CNP] signaling in the [disease development] of PAH and suggests that modulation of this pathway may provide a…
Cereno Scientific has been cleared to launch a Phase 1 clinical trial in Sweden to evaluate the pharmacological properties of CS014, its experimental oral treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The upcoming study in healthy volunteers was designed based on feedback from the U.S.
Scientists in China have uncovered key genetic drivers of the abnormal thickening of lung blood vessels that is a hallmark of idiopathic pulmonary arterial hypertension (IPAH), where the cause is unknown. By mapping individual lung cells and applying advanced tools, scientists identified two genes — POSTN and CCDC80…
Newly developed prediction models can identify infants with bronchopulmonary dysplasia (BPD) — a chronic lung condition that primarily affects premature newborns who need oxygen therapy — who are at the highest risk of developing pulmonary hypertension (PH), according to a large, multicenter study. After analyzing data from more than…
Higher blood levels of immunoglobulin E (IgE), an immune molecule typically linked to allergies, are associated with worse right heart function in people with pulmonary arterial hypertension (PAH), according to a study. While the left side of the heart pumps oxygen-rich blood to the body, the right side pumps…
People with pulmonary arterial hypertension (PAH) often have abnormalities in the coronary microvasculature, or the tiny blood vessels that are needed to deliver oxygen and nutrients to muscle cells in the heart, a small study shows. Importantly, problems with these blood vessels may contribute to heart disease and…
Scientists have developed an artificial intelligence-powered model that may help identify premature infants at risk for pulmonary hypertension (PH) and bronchopulmonary dysplasia (BPD) using noninvasive eye pictures taken during standard screenings. “Our findings suggest that information about a baby’s lung and heart health may already be present in these…
Following positive results from a Phase 3 clinical study, United Therapeutics plans to submit an application to the U.S. Food and Drug Administration (FDA) by the second half of 2026 seeking approval for its experimental oral therapy ralinepag as a treatment for pulmonary arterial hypertension (PAH). United announced…
GSK (formerly called GlaxoSmithKline) has acquired rights to HS235, an experimental treatment for pulmonary hypertension (PH), now in early clinical testing, that the buyer hopes will become a new standard of care for PH. The therapy’s developer 35Pharma announced that it’s being acquired by GSK for $950…
